Standard Biotools Shares Owned By Institutions vs. Price To Sales

LAB Stock  USD 1.93  0.11  6.04%   
Based on Standard Biotools' profitability indicators, Standard Biotools may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Standard Biotools' ability to earn profits and add value for shareholders. At present, Standard Biotools' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Days Of Sales Outstanding is expected to grow to 83.29, whereas Price To Sales Ratio is forecasted to decline to 1.56. At present, Standard Biotools' Total Other Income Expense Net is projected to decrease significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to about 474.6 K, whereas Accumulated Other Comprehensive Income is projected to grow to (2.1 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.630.4744
Significantly Up
Slightly volatile
For Standard Biotools profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Standard Biotools to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Standard Biotools utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Standard Biotools's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Standard Biotools over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.69)
Revenue Per Share
0.558
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.15)
Return On Equity
(0.37)
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Standard Biotools Price To Sales vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Standard Biotools's current stock value. Our valuation model uses many indicators to compare Standard Biotools value to that of its competitors to determine the firm's financial worth.
Standard Biotools is currently regarded as number one stock in shares owned by institutions category among its peers. It is rated third overall in price to sales category among its peers fabricating about  0.06  of Price To Sales per Shares Owned By Institutions. The ratio of Shares Owned By Institutions to Price To Sales for Standard Biotools is roughly  16.87 . At present, Standard Biotools' Price To Sales Ratio is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Standard Biotools' earnings, one of the primary drivers of an investment's value.

Standard Price To Sales vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Standard Biotools

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
73.33 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Standard Biotools

P/S

 = 

MV Per Share

Revenue Per Share

 = 
4.35 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Standard Price To Sales Comparison

Standard Biotools is currently under evaluation in price to sales category among its peers.

Standard Biotools Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Standard Biotools, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Standard Biotools will eventually generate negative long term returns. The profitability progress is the general direction of Standard Biotools' change in net profit over the period of time. It can combine multiple indicators of Standard Biotools, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-2.2 M-2.1 M
Operating Income-76.6 M-72.8 M
Income Before Tax-74.2 M-77.9 M
Total Other Income Expense Net2.4 M2.5 M
Net Loss-74.7 M-78.4 M
Income Tax Expense452 K474.6 K
Interest Income74.1 M77.8 M
Net Loss-171.1 M-162.5 M
Net Interest Income-4.7 M-4.9 M
Net Loss-75.7 M-79.5 M
Non Operating Income Net Other1.1 MM
Change To Netincome35.3 M22.8 M
Net Loss(0.94)(0.99)
Income Quality 0.58  0.70 
Net Income Per E B T 1.01  1.08 

Standard Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Standard Biotools. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Standard Biotools position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Standard Biotools' important profitability drivers and their relationship over time.

Use Standard Biotools in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Standard Biotools position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Standard Biotools will appreciate offsetting losses from the drop in the long position's value.

Standard Biotools Pair Trading

Standard Biotools Pair Trading Analysis

The ability to find closely correlated positions to Standard Biotools could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Standard Biotools when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Standard Biotools - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Standard Biotools to buy it.
The correlation of Standard Biotools is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Standard Biotools moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Standard Biotools moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Standard Biotools can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Standard Biotools position

In addition to having Standard Biotools in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials Thematic Idea Now

Financials
Financials Theme
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:
Check out Correlation Analysis.
For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
To fully project Standard Biotools' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Standard Biotools at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Standard Biotools' income statement, its balance sheet, and the statement of cash flows.
Potential Standard Biotools investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Standard Biotools investors may work on each financial statement separately, they are all related. The changes in Standard Biotools's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Standard Biotools's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.